Last reviewed · How we verify
Fluticasone proprionate 0.05% cream
Fluticasone propionate is a potent topical corticosteroid that suppresses local inflammatory and immune responses in the skin.
Fluticasone propionate is a potent topical corticosteroid that suppresses local inflammatory and immune responses in the skin. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).
At a glance
| Generic name | Fluticasone proprionate 0.05% cream |
|---|---|
| Also known as | Cutivate cream |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in skin cells, inhibiting the production of pro-inflammatory cytokines and mediators. This reduces inflammation, itching, and erythema associated with dermatological conditions. The 0.05% cream formulation provides moderate-to-high potency for topical application.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Seal, Stopping Eczema and Allergy Study (PHASE2)
- Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: